MK-677 (Ibutamoren) for Hip Fracture Recovery in Elderly Patients: A Trial Stopped Early for Heart Failure
MK-677 raised IGF-1 levels in elderly hip fracture patients but failed to improve most functional outcomes, and the trial was stopped early due to congestive heart failure cases.
Quick Facts
What This Study Found
In 123 elderly hip fracture patients randomized to MK-677 (25 mg/day) or placebo for 24 weeks, MK-677 significantly increased IGF-1 levels by 51.4 ng/ml compared to placebo (p < 0.001). Gait speed showed a modest but significant improvement (0.7-score difference, p = 0.011). However, stair climbing power did not significantly improve (12.5 W increase, p = 0.292), and several other functional measures showed no benefit.
The MK-0677 group had fewer falls than placebo, though this did not reach statistical significance (p = 0.096). Critically, the trial was terminated early due to a safety signal of congestive heart failure in a limited number of treated patients, leading to the conclusion that MK-677 has an unfavorable risk-benefit profile in elderly hip fracture patients.
Key Numbers
How They Did This
This was a multicenter, randomized, double-blind, placebo-controlled Phase IIb study. 123 elderly hip fracture patients were randomized to receive either 25 mg/day of oral MK-677 (n=62) or placebo (n=61). Primary outcomes were objective functional performance measures (stair climbing power, gait speed, and others) and blood IGF-1 levels, assessed over 24 weeks.
Why This Research Matters
MK-677 (ibutamoren) is one of the most popular growth hormone secretagogues in the peptide community. This trial provides critical safety data showing that raising IGF-1 doesn't automatically translate to functional improvement, and that MK-677 can cause serious cardiac side effects in vulnerable elderly patients. It's a cautionary study for anyone considering MK-677, particularly older adults.
The Bigger Picture
This trial is part of a larger story about whether raising growth hormone and IGF-1 levels can improve recovery and function in aging populations. While the biological rationale seemed sound — hip fracture patients lose muscle and function rapidly — the results highlight that pharmacologically boosting the GH/IGF-1 axis doesn't guarantee clinical benefit and can introduce serious risks. This has implications for the broader use of GH secretagogues in elderly populations.
What This Study Doesn't Tell Us
The trial was terminated early due to safety concerns, which means the study was underpowered to detect all potential functional benefits. The sample size of 123 is modest. The study focused on a specific elderly population recovering from hip fracture, and results may not apply to younger or healthier MK-677 users. The specific number of heart failure cases and their clinical details are not fully described in the abstract.
Questions This Raises
- ?Why did MK-677 raise IGF-1 significantly but fail to improve most functional outcomes — is there a disconnect between IGF-1 levels and muscle recovery in elderly patients?
- ?What was the mechanism behind the congestive heart failure cases — was it fluid retention, direct cardiac effects, or pre-existing vulnerability?
- ?Would lower doses of MK-677 retain any benefit while avoiding the cardiac safety signal?
Trust & Context
- Key Stat:
- Trial stopped early Terminated due to congestive heart failure signal in MK-677-treated elderly hip fracture patients despite significant IGF-1 increases
- Evidence Grade:
- This is a multicenter, randomized, double-blind, placebo-controlled Phase IIb trial — one of the strongest study designs. However, early termination reduced statistical power, and the safety signal adds important cautionary context to the findings.
- Study Age:
- Published in 2011, this remains one of the most important safety studies for MK-677 in elderly populations. The findings have not been superseded and continue to inform risk-benefit discussions about growth hormone secretagogues in vulnerable patients.
- Original Title:
- MK-0677 (ibutamoren mesylate) for the treatment of patients recovering from hip fracture: a multicenter, randomized, placebo-controlled phase IIb study.
- Published In:
- Archives of gerontology and geriatrics, 53(2), 183-9 (2011)
- Authors:
- Adunsky, Abraham, Chandler, Julie, Heyden, Norman, Lutkiewicz, Jeannine, Scott, Boyd B, Berd, Yuliya, Liu, Nancy, Papanicolaou, Dimitris A
- Database ID:
- RPEP-01727
Evidence Hierarchy
Frequently Asked Questions
What is MK-677 and why was it tested for hip fracture recovery?
MK-677 (ibutamoren) is an oral drug that stimulates growth hormone release by mimicking ghrelin. It was tested in hip fracture patients because muscle loss and functional decline after fracture are major problems in elderly patients, and growth hormone/IGF-1 promote muscle and bone recovery.
Does this mean MK-677 is dangerous for everyone?
This study specifically involved elderly patients recovering from hip fracture — a population already at high risk for heart problems. The congestive heart failure signal may be more relevant to older or medically fragile users. However, the fluid retention effects of MK-677 are well-documented and should be considered by anyone using it.
Read More on RethinkPeptides
Related articles coming soon.
Cite This Study
https://rethinkpeptides.com/research/RPEP-01727APA
Adunsky, Abraham; Chandler, Julie; Heyden, Norman; Lutkiewicz, Jeannine; Scott, Boyd B; Berd, Yuliya; Liu, Nancy; Papanicolaou, Dimitris A. (2011). MK-0677 (ibutamoren mesylate) for the treatment of patients recovering from hip fracture: a multicenter, randomized, placebo-controlled phase IIb study.. Archives of gerontology and geriatrics, 53(2), 183-9. https://doi.org/10.1016/j.archger.2010.10.004
MLA
Adunsky, Abraham, et al. "MK-0677 (ibutamoren mesylate) for the treatment of patients recovering from hip fracture: a multicenter, randomized, placebo-controlled phase IIb study.." Archives of gerontology and geriatrics, 2011. https://doi.org/10.1016/j.archger.2010.10.004
RethinkPeptides
RethinkPeptides Research Database. "MK-0677 (ibutamoren mesylate) for the treatment of patients ..." RPEP-01727. Retrieved from https://rethinkpeptides.com/research/adunsky-2011-mk0677-ibutamoren-mesylate-for
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.